Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen

Phenotypic Analysis of Antigen-Specific T Lymphocytes

1996 • 3,611 citations

Cancer immunotherapy: moving beyond current vaccines

2004 • 2,932 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

HUMAN T CELL RESPONSES AGAINST MELANOMA

2005 • 638 citations

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909

2005 • 619 citations

Translating Innate Immunity into Immunological Memory: Implications for Vaccine Development

2006 • 615 citations

Estimating the Precursor Frequency of Naive Antigen-specific CD8 T Cells

2002 • 584 citations

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

1996 • 566 citations

Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.

2011 • 539 citations

Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

1996 • 520 citations

High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals

1999 • 497 citations

Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues

1998 • 487 citations

Ex vivo identification, isolation and analysis of tumor-cytolytic T cells

2003 • 410 citations

High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy

1999 • 388 citations

Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance

2004 • 366 citations

Triggering TLR signaling in vaccination

2005 • 359 citations

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

1997 • 286 citations

Protective Immunity Does Not Correlate with the Hierarchy of Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides

1998 • 256 citations

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated antigens

1996 • 250 citations

Generation and maintenance of immunological memory

2004 • 234 citations

Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD8+ T cell response

2006 • 213 citations

Protective Immunity Does Not Correlate with the Hierarchy of Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides

1998 • 210 citations

Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL

2000 • 172 citations

Antigen Density Presented By Dendritic Cells In Vivo Differentially Affects the Number and Avidity of Primary, Memory, and Recall CD8+ T Cells

2003 • 113 citations

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

1998 • 112 citations

Adjuvant Immunization of HLA-A2–Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8⁺T-Cell Responses

2003 • 112 citations

T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.

2002 • 108 citations

Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection.

1992 • 107 citations

Poor immunogenicity of a self/tumor antigen derives from peptide–MHC-I instability and is independent of tolerance

2004 • 107 citations

Changes in the Fine Specificity of gp100(209–217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue

1999 • 103 citations

Vaccination with a Melan-A Peptide Selects an Oligoclonal T Cell Population with Increased Functional Avidity and Tumor Reactivity

2002 • 97 citations

A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.

1999 • 97 citations

Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in Humans

2002 • 97 citations

Diversity and Recognition Efficiency of T Cell Responses to Cancer

2004 • 96 citations

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

2004 • 73 citations

A Novel Approach to Characterize Clonality and Differentiation of Human Melanoma-Specific T Cell Responses: Spontaneous Priming and Efficient Boosting by Vaccination

2006 • 68 citations

Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.

2003 • 55 citations

Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells

2003 • 55 citations

A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.

2003 • 41 citations

Disease-driven T cell activation predicts immune responses to vaccination against melanoma.

2003 • 22 citations

Early acquisition of cytolytic function and transcriptional changes in a primary CD8+ T-cell response in vivo

2006 • 17 citations

IL-12 Controls Cytotoxicity of a Novel Subset of Self-Antigen-Specific Human CD28+ Cytolytic T Cells

2007 • 16 citations

GROWTH REQUIREMENTS OF DYSGONIC AND EUGONIC STRAINS OF MYCOBACTERIUM TUBERCULOSIS VAR. BOVIS

1952 • 15 citations